RTW Biotech Opportunities made an additional investment in Lycia Therapeutics as part of Lycia's $75 million Series D financing. The capital supports advancement of Lycia's clinical program, signaling continued investor backing for the biotech platform. The announcement is positive for both companies but is unlikely to materially move the broader market.
RTW Biotech Opportunities made an additional investment in Lycia Therapeutics as part of Lycia's $75 million Series D financing. The capital supports advancement of Lycia's clinical program, signaling continued investor backing for the biotech platform. The announcement is positive for both companies but is unlikely to materially move the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
